Scope of US Patent 8,633,194 (Levocetirizine liquid composition; 9:1 methyl/propyl parahydroxybenzoate preservative mix)
US Patent 8,633,194 claims a narrow, formulation-specific IP set: liquid levocetirizine (or a pharmaceutically acceptable salt) containing a preservative mixture of methyl parahydroxybenzoate (methyl paraben) and propyl parahydroxybenzoate (propyl paraben) at a fixed 9:1 weight ratio, with the total p-hydroxybenzoate ester level capped at 0.75 mg/mL and present in an amount greater than zero, in a composition described as “substantially free of bacteria.” Dependent claims narrow to aqueous systems, specific dosage forms (oral solutions, nasal/eye/ear drops), levocetirizine hydrochloride/dihydrochloride embodiments, and method-of-making via mixing the same components at the same 9:1 ratio. The patent estate is directed to preservative system choice and concentration, not to levocetirizine itself or broad “any preservative” formulations.
What patents protect levocetirizine liquid preservative systems (methyl/propyl paraben 9:1)?
Direct claim protection in US 8,633,194 is concentrated on:
- Active: levocetirizine or salt (including hydrochloride/dihydrochloride).
- Preservative system: methyl parahydroxybenzoate + propyl parahydroxybenzoate in a 9:1 weight ratio.
- Preservative level window: more than 0 and up to 0.75 mg/mL total p-hydroxybenzoate esters.
- Product condition: “substantially free of bacteria.”
- Liquid formats: aqueous; oral solutions and various ophthalmic/otic/nasal drops.
- Manufacturing step: mixing levocetirizine salt with the preservative mixture at the same 9:1 ratio.
H3. Independent claim 1: what is actually “the invention”?
Claim 1 ties the invention to a specific preservative mixture and concentration ceiling in a liquid levocetirizine composition that is substantially bacteria-free.
- Preservative composition:
- “a preservative mixture consisting essentially of a mixture of methyl p-hydroxybenzoate and propyl p-hydroxybenzoate in a ratio of 9/1 expressed in weight”
- Total preservative amount: >0 to 0.75 mg/mL
- Active ingredient: levocetirizine or salt (no fixed mg/mL required by claim 1).
- Product attribute: “substantially free of bacteria.” This typically functions as a functional/process-adjacent limitation tied to sterility assurance and/or microbial specification, but claim language is still in the composition.
H3. Dependent claims: what do they add?
- Claim 2: aqueous
- Claim 3: total p-hydroxybenzoate esters 0.0001 to 0.75 mg/mL
- Claim 4: dosage forms: oral solutions, nasal drops, eye drops, ear drops
- Claim 5: salt specified as levocetirizine hydrochloride
- Claim 6: explicit example composition at:
- levocetirizine hydrochloride 0.5 mg/mL
- methyl paraben 0.675 mg/mL
- propyl paraben 0.075 mg/mL
(Total p-hydroxybenzoate esters = 0.75 mg/mL; ratio 9:1)
- Claim 7: levorotatory enantiomer content: ≥95% by weight of the levorotatory enantiomer of cetirizine (i.e., levocetirizine purity/enantiomeric enrichment)
- Claims 8–10: method-of-making by mixing active salt with the 9:1 methyl/propyl paraben mixture (and optionally specifying the hydrochloride salt)
- Claims 11–12: explicit dose-form examples:
- Claim 11 (oral solution):
- levocetirizine dihydrochloride 0.50 mg/mL
- methyl paraben 0.675 mg/mL
- propyl paraben 0.075 mg/mL
- Claim 12 (oral drops):
- levocetirizine dihydrochloride 5.0 mg/mL
- methyl paraben 0.3375 mg/mL
- propyl paraben 0.0375 mg/mL
(Total p-hydroxybenzoate esters = 0.375 mg/mL; ratio 9:1)
How broad are the claims of US 8,633,194: does “consisting essentially of” limit competitors?
“Consisting essentially of” is the key constraint. It generally allows additional components that do not materially affect the basic and novel characteristics, here the preservative system consisting of methyl/propyl parahydroxybenzoates in a 9:1 ratio and the microbial/anti-microbial function.
H3. Practical claim-scope effects for formulation competitors
- You must keep the preservative system to methyl + propyl paraben at a 9:1 weight ratio to fall within claim 1 as written.
- You must keep total p-hydroxybenzoate esters ≤0.75 mg/mL and >0.
- The “consisting essentially of” language creates room for other formulation excipients (buffering agents, tonicity adjusters, viscosity modifiers, solubilizers) so long as they do not materially change the preservative characteristics. This is a fact-intensive boundary but, from a claim construction perspective, it blocks adding a different preservative as a “co-preservative” if that addition changes the basic preservative character.
H3. Design-around surfaces created by the claim language
A competitor can potentially avoid literal infringement by changing one of these anchor limitations:
- Change the ratio away from 9:1 (e.g., 10:1, 8:1, or switching to single parabens).
- Change the total paraben amount above 0.75 mg/mL, or use a “zero” paraben approach.
- Use a substantially different preservative system (e.g., phenoxyethanol, benzalkonium chloride, benzoic acid, etc.) in a way that changes the “basic and novel characteristics.”
- Make it non-9:1 even if methyl and propyl parabens remain present.
What specific dosage forms and salt forms are covered by US 8,633,194?
Claim coverage is not limited to one presentation. It spans multiple liquid delivery types.
H3. Dosage forms (explicit in dependent claim 4)
- oral solutions
- nasal drops
- eye drops
- ear drops
This matters for enforcement because infringement does not require a single label claim. If the formulation matches the claimed composition limits, route of administration language is a narrowing but still broad list.
H3. Salt embodiments
- levocetirizine free base is included in claim 1 (“levocetirizine or a pharmaceutically acceptable salt”)
- claim 5 and claim 10 focus on hydrochloride
- claims 11 and 12 use levocetirizine dihydrochloride in explicit examples (a specific salt form)
When does US 8,633,194 lose exclusivity and when can generics launch?
No exclusivity timing analysis can be produced from the claim text alone. Patent term, terminal disclaimers, and any regulatory exclusivity (including Orange Book-listed exclusivities tied to specific NDAs/ANDAs) depend on dossier-level facts and patent metadata. Without the filing/priority dates, patent issue date confirmation, and Orange Book listing linkage, the exclusivity timeline cannot be calculated accurately.
What Orange Book status would US 8,633,194 have for levocetirizine liquid products?
Orange Book status requires the NDA/ANDA identifier and the listing mapping between US 8,633,194 and specific NDA/ANDA products (including formulation descriptions and strength). Claim scope indicates a liquid levocetirizine preservative system, but listing status cannot be stated precisely without the Orange Book record.
What generic entry risks exist if a company reformulates levocetirizine drops with parabens?
The main infringement risk is compositional match. If a generic copies:
- levocetirizine salt form (hydrochloride/dihydrochloride or free base, depending on chosen embodiment),
- liquid format within the claimed dosage forms,
- aqueous system (if proceeding under claim 2),
- and most importantly the methyl/propyl paraben ratio of 9:1 with total paraben concentration >0 to ≤0.75 mg/mL,
then it fits the claim center of gravity.
H3. Claim 1 boundary conditions (the “do or don’t” checklist)
To reduce literal risk, a generic typically has to disrupt at least one of:
- paraben ratio: must deviate from 9:1
- total paraben: must be 0 or >0.75 mg/mL
- “substantially free of bacteria” is harder to design around because it is typically met through manufacturing controls and microbial specs rather than a deliberate “non-microbial-control” strategy.
- “consisting essentially of” can reduce risk if the preservative package is substantially different, not just adjusted.
H3. Example-level risk (claims 6, 11, 12)
The examples are close to market-credible label compositions:
- Oral solution example at 0.50 mg/mL active with 0.75 mg/mL total parabens at 9:1.
- Oral drops example at 5.0 mg/mL active with 0.375 mg/mL total parabens at 9:1.
A generic pursuing these numeric strengths and preservative amounts inherits direct match exposure.
How strong is the patent estate for this formulation: what is the likely claim construction posture?
Based on claim structure alone, the enforceability profile is driven by:
- High specificity on preservative ratio and concentration, which increases clarity for literal infringement but also narrows coverage.
- Functional bacterial wording (“substantially free of bacteria”), which may be construed in light of typical microbiological standards for liquid pharmaceuticals.
- Method claims that cover mixing, which can be implicated in manufacturing steps if the claimed components and ratio are used.
H3. Literal infringement “sweet spot”
The tight numeric ratio and cap on total paraben concentration create a defined “sweet spot.” Competitors using alternate ratios or higher/lower preservative levels reduce literal risk but may still create non-literal risks under equivalents depending on jurisdiction and prosecution history.
H3. Non-literal risk points
Even if the paraben ratio is adjusted slightly, arguments under doctrine of equivalents can arise if:
- the ratio change is insubstantial, and
- the preservative function and microbial control are materially the same.
Still, for a formulation patent with explicit 9:1 numeric constraint, courts often treat numeric thresholds as meaningful.
Which companies might be challenging or licensing similar preservative formulations?
No company challenge or licensing posture can be determined from claim text alone. Company identification requires litigation dockets, settlement records, and Orange Book Paragraph IV filings tied to levocetirizine liquid products.
What patent litigation affects levocetirizine liquid preservative formulations?
Litigation status for US 8,633,194 cannot be produced without docket-level data linking this specific patent to cases, defendants, and FDA products. Claim text does not support any reliable inference about enforcement actions.
Does US 8,633,194 cover manufacturing methods, or just the final composition?
It covers both.
H3. Method claims 8–10
- Claim 8: mixing levocetirizine salt with methyl/propyl parahydroxybenzoate mixture at 9:1
- Claim 9: mixing a pharmaceutically acceptable salt (again at 9:1)
- Claim 10: salt is hydrochloride
Method coverage can be relevant where composition claims are harder to prove due to sampling or where manufacturing records show the exact mixing recipe.
H3. Infringement evidence typical for method claims
- batch manufacturing records showing the preservative amounts and ratios,
- component COAs that verify paraben identities,
- formulation worksheets used for scale-up.
How does US 8,633,194 compare with broader “levocetirizine solution” patents?
From a claim-scope standpoint, US 8,633,194 is narrower than patents covering:
- any levocetirizine liquid formulation regardless of preservative,
- broader preservative families,
- generic “all aqueous solutions” without ratio/concentration constraints.
It is closer to a “preservative system selection” patent that claims a specific preservative composition (9:1) and specific concentration limits in a levocetirizine liquid context.
H3. Competition implications
- If a competitor uses a different preservative system, the patent is less likely to capture the product.
- If a competitor uses the same preservatives but changes ratio or total levels, it can avoid the core numeric limitations.
- If a competitor replicates the same ratio and cap range, freedom-to-operate risk rises sharply.
Key claim chart for US 8,633,194 (what must be true for infringement)
| Element |
Claim 1 requirement |
Covered by dependents |
Notes |
| Active |
levocetirizine or salt |
claim 5/6/11/12 |
Salt forms include hydrochloride/dihydrochloride in examples |
| Dosage form |
liquid pharmaceutical composition |
claim 4 |
oral solution; nasal/eye/ear drops |
| Solvent |
not required by claim 1 |
claim 2 |
aqueous is explicitly required by claim 2 |
| Preservative system |
methyl p-hydroxybenzoate + propyl p-hydroxybenzoate |
all composition claims |
“consisting essentially of” language limits additions that change basic characteristics |
| Preservative ratio |
9/1 (w/w) |
all |
central numeric limitation |
| Preservative amount |
>0 to 0.75 mg/mL |
claim 3 tightens lower bound |
claim 3: 0.0001 to 0.75 mg/mL |
| Bacteria condition |
substantially free of bacteria |
all |
functional composition limitation |
| Example embodiments |
specific strengths/amounts |
claims 6, 11, 12 |
direct numeric match if product mirrors examples |
Key Takeaways
- US 8,633,194 is a formulation patent centered on a fixed 9:1 methyl/propyl parahydroxybenzoate preservative mixture at total p-hydroxybenzoate ester levels up to 0.75 mg/mL in liquid levocetirizine products described as substantially free of bacteria.
- The narrow, numeric character of the ratio and concentration cap creates clear literal infringement boundaries and straightforward design-around levers (ratio and/or total paraben level; preservative system substitution that changes basic characteristics).
- The estate includes both composition claims and method-of-making claims covering mixing the same components at the same 9:1 ratio.
- Exclusivity timelines, Orange Book status, and Paragraph IV/litigation risk cannot be determined from the claim text alone.
FAQs
-
If a levocetirizine liquid uses methyl and propyl parabens at a 9:1 ratio but total paraben is 0.8 mg/mL, is it within claim 1?
Claim 1 caps total p-hydroxybenzoate esters at up to 0.75 mg/mL, so 0.8 mg/mL is outside the stated range.
-
Does claim 1 require the levocetirizine salt to be hydrochloride?
No. Claim 1 covers levocetirizine or any pharmaceutically acceptable salt; hydrochloride is specifically required in dependent claim 5.
-
Are only oral solutions covered?
No. Dependent claim 4 includes oral solutions, nasal drops, eye drops, and ear drops.
-
What protects manufacturing steps under this patent?
Claims 8–10 cover a mixing method using levocetirizine (salt) with the 9:1 methyl/propyl paraben mixture.
-
Can the formulation include other excipients besides methyl and propyl parabens?
Claim 1 uses “consisting essentially of,” allowing other components so long as they do not materially affect the preservative system’s basic characteristics.
References (APA)
- United States Patent 8,633,194.
